Clinical trial Recruiting at 1 site Interventional Ages 18 to 64

Using dry needling to treat muscle tightness in people with Multiple Sclerosis

Official title: The Effectiveness of Dry Needling on Reducing Spasticity and Promoting Mobility and Balance in People With Multiple Sclerosis

Run by University of Kansas Medical Center · NCT06394310 · Data updated 2026-11-12

This study is testing if dry needling can help people with Multiple Sclerosis reduce muscle tightness and improve their balance and walking.

More Multiple Sclerosis trials

Quick facts

Study typeInterventional
Ages18 Years to 64 Years
SexAll
Enrollment24 (estimated)
SponsorUniversity of Kansas Medical Center
Academic / other
Locations1 site (Kansas City, Kansas)
StatusRecruiting
StartedMay 1, 2024
Main results expectedJuly 2, 2025
Study endsAugust 1, 2025
Registry record updatedJune 11, 2025
Trial IDNCT06394310 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 64 with a clinical diagnosis of Multiple Sclerosis and spasticity in their lower legs.

Probably not a fit

Patients with severe varicose veins, needle phobia, or other significant medical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of dry needling as a treatment for muscle spasticity in individuals diagnosed with Multiple Sclerosis. Dry needling involves the insertion of thin needles into specific muscle areas to alleviate tightness and pain, differing from traditional acupuncture by focusing on muscle management. The study aims to determine if this minimally-invasive technique can improve not only muscle stiffness but also enhance balance and walking abilities, potentially leading to better overall mobility. Participants will be compared against a sham dry needling group to assess the treatment's efficacy.

Why it matters

Potential benefit: If successful, this treatment could provide a medication-free option to improve muscle spasticity and mobility for patients with Multiple Sclerosis.

How similar studies have gone: While dry needling is a recognized technique, its application specifically for Multiple Sclerosis is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 to 64 years
* Clinical diagnosis of Multiple Sclerosis based on the McDonald Criteria
* Spasticity in their lower legs
* Patient Determined Disease Steps (PDDS) score of 5 or below

Exclusion Criteria:

* Inability to communicate effectively with study personnel
* Needle phobia
* Severe varicose veins
* Presence of an active implanted device
* Pregnancy
* Any active cancer or history within 1 year
* known or suspected infection at the site of needling or in the surrounding area
* Presence of a fixed plantarflexion contracture at the ankle
* Acute fracture of dislocation in the region (bilateral lower extremity)
* Deep vein thrombosis or peripheral vascular disease
* Thrombophlebitis, or active osteomyelitis in the region (bilateral lower extremity)
* Any medication changes, including antispastic medicines, for the past three months.

Where it's running

  • Mobility and Falls Lab
    Kansas City, Kansas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.